Pulse Biosciences (NASDAQ:PLSE) COO Acquires $49,999.95 in Stock

Pulse Biosciences, Inc (NASDAQ:PLSE) COO Liane Teplitsky bought 1,001 shares of the firm’s stock in a transaction dated Tuesday, September 1st. The stock was purchased at an average price of $49.95 per share, with a total value of $49,999.95. Following the transaction, the chief operating officer owned 4,095 shares in the company, valued at approximately $204,545.25. This represents a 32.35% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Liane Rae Teplitsky also recently made the following trade(s):

• On Monday, August 31st, Liane Teplitsky purchased 1,024 shares of Pulse Biosciences stock. The stock was purchased at an average price of $48.80 per share, with a total value of $49,971.20.
• On Friday, August 28th, Liane Teplitsky purchased 1,034 shares of Pulse Biosciences stock. The shares were purchased at an average cost of $48.35 per share, for a total transaction of $49,993.90.
• On Wednesday, August 26th, Liane Teplitsky acquired 1,036 shares of Pulse Biosciences stock. The shares were purchased at an average price of $48.23 per share, for a total transaction of $49,966.28.

Pulse Biosciences Price Performance

Pulse Biosciences stock opened at $53.24 on Friday. The company has a market cap of $3.68 billion, a PE ratio of -45.12 and a beta of 1.63. The company has a fifty day moving average price of $37.97 and a two-hundred day moving average price of $28.00. Pulse Biosciences, Inc has a 12 month low of $12.56 and a 12 month high of $55.37.

Pulse Biosciences (NASDAQ:PLSE) last released its earnings results on Thursday, August 6th. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.07). The business had revenue of $0.43 million for the quarter, compared to the consensus estimate of $0.53 million. Pulse Biosciences had a negative net margin of 6,755.78% and a negative return on equity of 94.42%. Equities research analysts anticipate that Pulse Biosciences, Inc will post -1.29 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of PLSE. Osterweis Capital Management Inc. acquired a new position in shares of Pulse Biosciences during the second quarter worth approximately $28,000. BNP Paribas Financial Markets increased its position in Pulse Biosciences by 63.6% in the 2nd quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company’s stock valued at $26,000 after acquiring an additional 680 shares during the period. Tower Research Capital LLC TRC raised its stake in Pulse Biosciences by 275.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company’s stock valued at $44,000 after acquiring an additional 2,156 shares in the last quarter. Russell Investments Group Ltd. boosted its position in Pulse Biosciences by 44.0% during the 3rd quarter. Russell Investments Group Ltd. now owns 4,487 shares of the company’s stock worth $79,000 after acquiring an additional 1,372 shares during the period. Finally, Jupiter Topco LLC bought a new position in shares of Pulse Biosciences in the second quarter worth $241,000. Institutional investors own 76.95% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the stock. Needham & Company LLC assumed coverage on shares of Pulse Biosciences in a research note on Monday, August 17th. They set a “buy” rating and a $58.00 price objective on the stock. Mizuho set a $45.00 target price on Pulse Biosciences in a report on Monday, August 10th. Oppenheimer reiterated an “outperform” rating on shares of Pulse Biosciences in a research report on Tuesday, July 28th. Wall Street Zen raised Pulse Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, August 29th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Pulse Biosciences in a research report on Friday, July 17th. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Pulse Biosciences presently has an average rating of “Moderate Buy” and a consensus price target of $45.25.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.